Company Profile

Stemline Therapeutics Inc
Profile last edited on: 7/28/17      CAGE: 4CJM1      UEI:

Business Identifier: Cancer treatments targeting cancer stems cells and tumor bulk
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

750 Lexington Avenue 11th Floor
New York, NY 10022
   (646) 502-2310
Location: Single
Congr. District: 12
County: New York

Public Profile

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $174,785
Project Title: Development of SL-101, an Immunotoxin that Targets Cancer Stem Cells

Key People / Management

  Ivan Bergstein -- Chief Executive Officer

  Kenneth Hoberman -- CEO

  Tom Cirrito -- Director Of Operations

  Malcolm A Moore

  Eric Rowinsky -- Chief Medical Officer and Head of R&D